Cancer Biosimilars Market Size, Share & Trends Analysis Report By Type (Lung Cancer, Breast cancer, Ovarian cancer, Prostate cancer, Lymphoma, Others), By Distribution Channel, By Drug Class, By Route of Administration, Region And Segment Forecasts, 2023-2031
Global Cancer Biosimilars Market Segmentation
Global Cancer Biosimilars Market Outlook By Biologic class
- Bevacizumab
- Rituximab
- Trastuzumab
- Filgrastim
- Pegfilgrastim
- Denosumab
- Others (Products approved in developing countries & pipeline products)
Global Cancer Biosimilars Market Outlook By Type
- Lung Cancer
- Breast cancer
- Ovarian cancer
- Prostate cancer
- Lymphoma
- Others
Global Cancer Biosimilars Market Outlook By Drug Class
- G-CSF
- Monoclonal Antibody
Global Cancer Biosimilars Market Outlook By Route Of Administration
- Intravenous
- Subcutaneous
- Others
Global Cancer Biosimilars Market Outlook By Distribution channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Cancer Biosimilar Market Outlook By Region
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- North America
- U.S.
- Canada
- Asia Pacific
- India
- China
- Japan
- South Korea
- Australia & New Zealand
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biosimilars Market Snapshot
Chapter 4. Global Cancer Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Biologic Class Estimates & Trend Analysis
5.1. By Biologic Class & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Biologic Class:
5.2.1. Bevacizumab
5.2.2. Rituximab
5.2.3. Trastuzumab
5.2.4. Filgrastim
5.2.5. Pegfilgrastim
5.2.6. Denosumab
5.2.7. Others (Products approved in developing countries & pipeline products)
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Type:
6.2.1. Lung Cancer
6.2.2. Breast cancer
6.2.3. Ovarian cancer
6.2.4. Prostate cancer
6.2.5. Lymphoma
6.2.6. Others
Chapter 7. Market Segmentation 3: By Drug Class Estimates & Trend Analysis
7.1. By Drug Class & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Drug Class:
7.2.1. G-CSF
7.2.2. Monoclonal Antibody
Chapter 8. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis
8.1. By Route of Administration & Market Share, 2021 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Route of Administration:
8.2.1. Intravenous
8.2.2. Subcutaneous
8.2.3. Others
Chapter 9. Market Segmentation 5: By Distribution Channel Estimates & Trend Analysis
9.1. By Distribution Channel & Market Share, 2021 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Distribution Channel:
9.2.1. Hospital Pharmacy
9.2.2. Retail Pharmacy
9.2.3. Online Pharmacy
9.2.4. Others
Chapter 10. Cancer Biosimilars Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.1.2. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.1.3. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.1.4. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.1.5. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.1.6. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2025 - 2034
10.2. Europe
10.2.1. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.2.2. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.2.3. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.2.4. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.2.5. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.2.6. Europe Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.3.2. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.3.3. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.3.4. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.3.5. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.3.6. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.4. Latin America
10.4.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.4.2. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.4.3. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.4.4. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.4.5. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.4.6. Latin America Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.5.2. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.5.3. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.5.4. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.5.5. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.5.6. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Mylan
11.2.2. Amgen
11.2.3. Pfizer
11.2.4. Celltrion
11.2.5. Samsung Bioepis
11.2.6. Bio-Thera Solutions
11.2.7. Sandoz (Novartis)
11.2.8. Teva
11.2.9. Coherus BioSciences
11.2.10. CuraTeQ Biologics
11.2.11. Accord Healthcare
11.2.12. Allergan
11.2.13. Biocon
11.2.14. Merck
11.2.15. Accord BioPharma
11.2.16. Accord Healthcare S.L.U.
11.2.17. AffaMed
11.2.18. Biosimilar Collaborations Ireland Limited
11.2.19. Dr. Reddy’s
11.2.20. Henlius
11.2.21. Intas
11.2.22. Mabxience
11.2.23. Nippon Kayaku
11.2.24. Sandoz GmbH
11.2.25. Amgen Inc.
11.2.26. Amneal Pharmaceuticals, Inc.
11.2.27. Betta Pharmaceuticals/Beijing Mabworks
11.2.28. Bio-Thera Solutions, Ltd.
11.2.29. Celltrion, Inc.
11.2.30. Cipla
11.2.31. Dr. Reddy’s Laboratories
11.2.32. FGK Representative Service GmbH
11.2.33. Hetero
11.2.34. Innovent Biologics
11.2.35. mAbxience Holding, S.L.
11.2.36. Outlook Therapeutics Limited
11.2.37. Pfizer Inc.
11.2.38. Roche Registration GmbH
11.2.39. Samsung Bioepis NL B.V.
11.2.40. Sandoz Inc.
11.2.41. Shanghai Henlius Biotech
11.2.42. STADA Arzneimittel AG
11.2.43. TOT BIOPHARM
11.2.44. AstraZeneca PLC
11.2.45. Samsung Bioepis Co., Ltd.
11.2.46. Organon & Co.
11.2.47. Other Prominent Player
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031.
Mylan, Amgen, Pfizer, Celltrion, Samsung Bioepis, Bio-Thera Solutions, Sandoz (Novartis), Teva, Coherus BioSciences, CuraTeQ Biologics, Accord Healthc
Biologic Class, Type, Distribution Channel, Drug Class, and Route of Administration are the key segments of the Cancer Biosimilars Market.
North American region is leading the Cancer Biosimilars Market.